294
Views
0
CrossRef citations to date
0
Altmetric
Review

Current and emerging pharmacotherapy for pediatric allergic rhinitis

&
Pages 849-855 | Received 29 Apr 2020, Accepted 07 Aug 2020, Published online: 18 Aug 2020
 

ABSTRACT

Introduction

Allergic rhinitis (AR) is a global health problem in adults as well as the younger population, continuously increasing and posing a significant problem for patients, health care systems and economies. For the younger population, some aspects differ from treatment of adults, namely, prevention, compliance and adherence.

Areas covered

This narrative review summarizes all the pharmacotherapeutic options with special focus on the pediatric population. Moreover, it elucidates prevention strategies as well as future developments of AR treatment. Currently, symptomatic therapy in the form of steroids and antihistamines is applied topically and systemically where steroids need to be administered with caution and for a very short term. The only disease-modifying and causal treatment is allergen immunotherapy administered sublingually and subcutaneously. Future and current novel therapeutic options are human monoclonal antibodies.

Expert opinion

The greatest potential for future developments currently lie in allergen immunotherapy and here in different routes of administration and modification of (recombinant) allergens as well as immune‐modulating adjuvants and nanoparticles. Secondly, monoclonal antibodies are promising molecules blocking and/or interfering with up- and downstream immune mechanisms. Another important aspect lies in prevention of allergic sensitization and disease progression through both AIT and biologics which is particularly true for the pediatric population.

Article highlights

  • Specific IgE sensitization and production in childhood is a major risk of developing multimorbidities and allergic rhinitis and asthma in late childhood and adolescence

  • Nasal corticosteroids are well tolerated, act fast especially relieving nasal congestion and work best when combined with topical antihistamines

  • SLIT and SCIT work well in children with applications routes impacting compliance

  • Biologics provide symptom relief, are very well tolerated with little side effects and seem to have a synergistic effect with immunotherapy

  • Omalizumab and Dupilumab are promising Biologics in treatment of pediatric allergic rhinitis and have multiple ways of acting anti-inflammatory

This box summarizes key points contained in the article.

Acknowledgments

The authors thank Laurie Murray for her effort in editing our manuscript.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This manuscript has not been funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.